V.V. Goncharuk

Vinnytsya National Pirogov Memorial Medical University, Vinnytsya, Ukraine


Summary. Intravesical administration of chemopreparations is widely used in clinical practice and in experiments. However, there are practically no data on morphological changes during the action of chemotherapy drugs on the mucous membrane of the urinary bladder. Aim: to establish the patterns of morphological changes in the layers of the bladder wall during intravesical administration of epirubicin. Object and methods: the studies use white outbred rats (females, weight 200-250 g). Epirubicin was administered intravesically. Morphological changes of the bladder wall were assessed by light microscopy of fixed preparations of cells stained with hematoxylin and eosin after 2 hours; 3, 7 and 21 days after administration of the epirubicin. The obtained results were analyzed by the method of variational statistics. Results: the obtained data indicate significant disorders on the side of the bladder wall, namely atrophic changes and fibrosis of the submucosal base. Morphological changes indicated circulatory disorders in the vessels of the bladdemucous membrane and the submucosal base, which was accompanied by a significant nonspecific inflammatory reaction. Conclusions: obtained morphological and morphometric data indicate significant changes in the bladder wall of rats under the action of the chemotherapy drug epirubicin.

Keywords: bladder, mucous membrane, submucosa, bladder cancer, chemotherapy.



  1. Saginala K, Barsouk A, Aluru JS, et al. Epidemiology of bladder cancer. Med Sci (Basel) 2020; 8 (1): 15. doi: 10.3390/medsci8010015.
  2.  Mangsbo SM, Ninalga C, Essand M, et al. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. J Immunother 2008; 31 (1): 34– doi: 10.1097/CJI.0b013e3181587d29.
  3.  Zaharoff DA, Hoffman BS, Hooper HB, et al. Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. Cancer Res 2009; 69 (15): 6192– doi: 10.1158/0008-5472.CAN-09-1114.
  4. Halachmi S, Moskovitz B, Maffezzini M, et al. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol 2011; 29 (3): 259– doi: 10.1016/j.urolonc.2009.02.012.
  5. Pasichnyk SM. Application of local chemotherapy in the treatment of superficial forms of bladder cancer. ACTA. Lviv Medical Journal 2012; 18 (2): 65–8. (in Ukrainian).
  6. Kostyuk OG, Hnatiuk MS. Morphometric assessment of features of the regeneration of the mucous membrane of the urinary bladder after its removal. Vinnytsia state university 2008; 12 (1): 21–4. (in Ukrainian).
  7. Kostyuk OG, Kavka MP, Bezkorovainy JE. A new method of treating superficial bladder cancer. Clinic anatomy and operative surgery 2008; (1): 85–6. (in Ukrainian).
  8. Kostyuk OG. Ways to improve the pharmacokinetics of antitumor chemopreparations in the treatment of superficial bladder cancer. Clinic anatomy and operative surgery 2011; (1): 75–8. (in Ukrainian).
  9. Dumanskyi YuY, Kostyuk OG, Kostyuk GY. A new approach to the treatment of superficial bladder cancer. Problems, achievements and prospects for the development of medical and biological scientists 2010; 146 (2): 59–61. (in Ukrainian).
  10. Коstyev FI, Bondar OV, Chystiakov RS, Lysenko VV. Impact of adjuvant intrabladder therapy on quality of life in patients, suffering musculo–noninvasive cancer of the bladder. Klinichna khirurhiia 2020; 87 (7–8): 47–52. doi: 10.26779/2522-1396.2020.7-8.47.
  11. Kostyuk OG. Morphological changes in the tissues of the urinary bladder in the long term after submucosal administration of doxorubicin solution. Herald of morphology 2009; 15 (1): 24–6. (in Ukrainian).

No comments » Add comment